Antikörper gegen Erythrozyten und Thrombozyten in der Schwangerschaft und deren perinatales Management

Ob irreguläre Antikörper gegen Erythrozyten oder Thrombozyten den Schwangerschaftsverlauf für Mutter oder Kind komplizieren, hängt von vielen verschiedenen Faktoren ab. Dieser Artikel beleuchtet die Pathophysiologie der fetalen/neonatalen Hämolyse und das pränatale Management bei vorliegenden Alloantikörpern gegen Erythrozyten sowie Erkrankungen, die mit Allo- oder Autoantikörpern gegen Thrombozyten einhergehen.

Schlüsselwörter

Alloantikörper - Autoimmunantikörper - Blutgruppenantigene - HDFN - Rhesusfaktor - ITP

• Literatur

• 1 Egbor M, Knott P, Bhide A. Red-cell and platelet alloimmunisation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2012; 26: 119-132 doi:10.1016/j.bpobgyn.2011.10.004
• 2 Hadley AG. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transpl Immunol 2002; 10: 191-198
• 3 Geifman-Holtzman O, Wojtowycz M, Kosmas E. et al. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997; 89: 272-275 doi:10.1016/s0029-7844(96)00434-6
• 4 Moise jr. KJ, Kennedy MS. Management of non-Rh(D) red blood cell alloantibodies during pregnancy. Im Internet: https://www.uptodate.com/contents/management-of-non-rh-d-red-blood-cell-alloantibodies-during-pregnancy Stand: 16.01.2019
• 5 Dajak S, Stefanovic V, Capkun V. Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening (CME). Transfusion 2011; 51: 1380-1388 doi:10.1111/j.1537-2995.2010.03006.x
• 6 Axt-Fliedner R, Wienzek-Lischka S, Sachs U. et al. Hämolytische Erkrankung des Fetus und Neugeborenen Teil 1: Ätiologie, Pathogenese, Diagnostik und Therapie in der Schwangerschaft. Transfusionsmedizin 2018; 8: 95-110
• 7 Koelewijn JM, Vrijkotte TG, van der Schoot CE. et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48: 941-952 doi:10.1111/j.1537-2995.2007.01625.x
• 8 de Haas M, Thurik FF, Koelewijn JM. et al. Haemolytic disease of the fetus and newborn. Vox Sang 2015; 109: 99-113 doi:10.1111/vox.12265
• 9 ACOG Practice Bulletin No. 192: Management of alloimmunization during pregnancy. Obstet Gynecol 2018; 131: e82-e90 doi:10.1097/aog.0000000000002528
• 10 Moise KJ. Management of pregnancy complicated by Rh(D) alloimmunization. Im Internet: https://www.uptodate.com/contents/management-of-pregnancy-complicated-by-rh-d-alloimmunization Stand: 16.01.2019
• 11 Flegel WA, Wagner FF. Molecular biology of partial D and weak D: implications for blood bank practice. Clin Lab 2002; 48: 53-59
• 12 Egbor M, Arraut A, Tran SH. et al. Erythrocyte alloimmunization and pregnancy. eMedicine Journal 2011. Im Internet: http://emedicine.medscape.com/article/273995-overview Stand: 01.07.2019
• 13 Gunson HH, Stratton F, Phillips PK. The primary Rho(D) immune response in male volunteers. Br J Haematol 1976; 32: 317-329
• 14 Qureshi H, Massey E, Kirwan D. et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfusion Medicine 2014; 24: 8-20
• 15 Moise jr. KJ, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120: 1132-1139 doi:10.1097/AOG.0b013e31826d7dc1
• 16 Stetson B, Scrape S, Markham KB. Anti-M alloimmunization: management and outcome at a single institution. AJP Reports 2017; 7: e205-e210 doi:10.1055/s-0037-1607028
• 17 Mollison P. Mollisonʼs Blood Transfusion in clinical Medicine. 12th edition. Chicester, West Sussex: Wiley Blackwell; 2014
• 18 Surendran SAllard S, Regan F. The Management of Women with Red Cell Antibodies during Pregnancy. RCOG Green-top Guideline No. 65. 2014
• 19 Salaba A, Mayer B, Bamberg C. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zum Thema D16-01 Nichtinvasive Bestimmung des fetalen Rhesusfaktors zur Vermeidung einer mütterlichen Rhesus-Sensibilisierung. Geburtsh Frauenheilkd 2018; 78: 561-562 doi:10.1055/a-0632-0676
• 20 Mari G, Deter RL, Carpenter RL. et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342: 9-14 doi:10.1056/nejm200001063420102
• 21 Wong KS, Connan K, Rowlands S. et al. Antenatal immunoglobulin for fetal red blood cell alloimmunization. Cochrane Database Syst Rev 2013;
• 22 Mayer B, Hinkson L, Hillebrand W. et al. Efficacy of antenatal intravenous immunoglobulin treatment in pregnancies at high risk due to alloimmunization to red blood cells. Transfusion Med Hemother 2018; 45: 429-436 doi:10.1159/000490154
• 23 Schwartz J, Padmanabhan A, Aqui N. et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apheresis 2016; 31: 149-162 doi:10.1002/jca.21470
• 24 Neunert C, Lim W, Crowther M. et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207 doi:10.1182/blood-2010-08-302984
• 25 Bergmann F, Rath W. The differential diagnosis of thrombocytopenia in pregnancy. Dtsch Arztebl Int 2015; 112: 795-802 doi:10.3238/arztebl.2015.0795
• 26 Kiefel V. Immunologische Diagnostik bei Thrombozytopenie. Dtsch Arztebl 2003; 100: A-2159/B-1798/C-1702
• 27 Maayan-Metzger A, Leibovitch L, Schushan-Eisen I. et al. Predictors for neonatal thrombocytopenia in infants of thrombocytopenic mothers during pregnancy. Pediatr Blood Cancer 2010; 55: 145-148 doi:10.1002/pbc.22514
• 28 Bussel J, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Bailliereʼs Clin Haematol 1998; 11: 391-408
• 29 Winkelhorst D, Oepkes D. Foetal and neonatal alloimmune thrombocytopenia. Best Pract Res Clin Obstet Gynaecol 2019;
• 30 Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Diseases 2006; 1: 39 doi:10.1186/1750-1172-1-39
• 31 Regan F, Lees CC, Jones B. et al. Prenatal management of pregnancies at Rrisk of fetal neonatal alloimmune thrombocytopenia (FNAIT): Scientific Impact Paper No. 61. Br J Obstet Gynaecol 2019; 126: e173-e185 doi:10.1111/1471-0528.15642
• 32 Kiefel V, Bassler D, Kroll H. et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006; 107: 3761-3763 doi:10.1182/blood-2005-06-2235